Word

KYMAB

Status

Registered

Status Code

700

Status Date

Tuesday, September 7, 2021

Serial Number

88441516

Registration Number

6473731

Registration Date

Tuesday, September 7, 2021

Mark Type

4000

Filing Date

Wednesday, May 22, 2019

Published for Opposition

Tuesday, March 23, 2021

Trademark Owner History

Kymab Limited - Original Registrant

Classifications

5 Pharmaceutical and medical preparations containing monoclonal antibodies for the treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; Veterinary preparations containing monoclonal antibodies for treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, autoimmune and infectious diseases, and medical diagnostics; sanitary preparations containing monoclonal antibodies for medical purposes; dietetic food and beverages containing monoclonal antibodies, for medical and veterinary use; dietary supplements containing monoclonal antibodies for human beings and animals; dietary supplements containing monoclonal antibodies; Pharmaceutical preparations containing monoclonal antibodies for the treatment of treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases and in the field of antibodies and immuno-oncology

42 Scientific, medical and technological services, namely, scientific research, analysis and testing in the field of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology, and scientific research, analysis and testing in the field of antibodies and cell repertoires and research, development and design in the field of science, medicine, and technology; industrial analysis and industrial research services, namely, testing, analysis, and evaluation of the goods of others to assure compliance with industry standards; design and development of computer hardware and software; design and development of hardware and software for analysis and testing in the field of antibodies and biological cells and genetic discovery and clinical development; Clinical research in the field of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodies, immuno-oncology, inflammation, haematology and infectious disease; Conducting clinical trials for others in the field of antibodies, and medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; conducting clinical trials for pharmaceutical products for others in the field of medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; scientific and medical screening and assaying of medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; scientific and medical screening and assaying in the field of genetic discovery, clinical development, antibodies and biological cells; chemical analysis; chemical research

44 Medical services; diagnostic and prognostic medical services; veterinary services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pharmaceutical consultation in the nature of pharmacy advice; medical and health services in the nature of the treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics; Medical screening

Trademark Events

Sep 7, 2021

Registered-Principal Register

Aug 1, 2021

Extension Of Time To Oppose Process - Terminated

Apr 21, 2021

Extension Of Time To Oppose Received

Mar 23, 2021

Official Gazette Publication Confirmation E-Mailed

Mar 23, 2021

Published For Opposition

Mar 3, 2021

Notification Of Notice Of Publication E-Mailed

Feb 17, 2021

Approved For Pub - Principal Register

Feb 17, 2021

Examiner's Amendment Entered

Feb 17, 2021

Notification Of Examiners Amendment E-Mailed

Feb 17, 2021

Examiners Amendment E-Mailed

Feb 17, 2021

Examiners Amendment -Written

Oct 9, 2020

Notification Of Non-Final Action E-Mailed

Oct 9, 2020

Non-Final Action E-Mailed

Oct 9, 2020

Non-Final Action Written

Aug 22, 2020

Teas/Email Correspondence Entered

Aug 21, 2020

Correspondence Received In Law Office

Aug 21, 2020

Teas Response To Office Action Received

Mar 16, 2020

Notification Of Non-Final Action E-Mailed

Mar 16, 2020

Non-Final Action E-Mailed

Mar 16, 2020

Non-Final Action Written

Mar 9, 2020

Previous Allowance Count Withdrawn

Feb 21, 2020

Electronic Record Review Complete

Feb 21, 2020

On Hold - Electronic Record Review Required

Feb 14, 2020

Approved For Pub - Principal Register

Feb 14, 2020

Examiner's Amendment Entered

Feb 14, 2020

Notification Of Examiners Amendment E-Mailed

Feb 14, 2020

Examiners Amendment E-Mailed

Feb 14, 2020

Examiners Amendment -Written

Jan 29, 2020

Teas/Email Correspondence Entered

Jan 28, 2020

Correspondence Received In Law Office

Jan 28, 2020

Teas Response To Office Action Received

Aug 9, 2019

Notification Of Non-Final Action E-Mailed

Aug 9, 2019

Non-Final Action E-Mailed

Aug 9, 2019

Non-Final Action Written

Aug 9, 2019

Assigned To Examiner

Jun 6, 2019

New Application Office Supplied Data Entered In Tram

May 25, 2019

New Application Entered In Tram